Everyday Epigenetics

Small choices, big outcomes.

A Biogenetix Clinical Presentation BIOGENETIX.COM



Disclaimer

- Information in this presentation is not intended to diagnose, treat, reverse, cure, or prevent any disease. While this presentation is based on medical literature, findings, and text, The following statements have not been evaluated by the FDA.
- The information provided in this presentation is for your consideration only as a practicing health care provider. Ultimately you are responsible for exercising professional judgment in the care of your own patients.



Epigenetics:

Study of changes in the DNA that do not involve changes in the DNA sequence.




Environment + Genetics = Chronic Health Condition








Environment + Genetics = Chronic Health IMPROVEMENT














68 yo male, DM2, CD. MRI 1

MORPHOMETRY RESULTS







Intracranial Volume (ICV)	ICV Percentile		Cortical Brain Regions	Percentiles			
(cm ³)					Left	Right	Total
1664.83		60		Frontal Lobes	19	11	14
Total Volumes		Percentiles		Superior Frontal	60	24	39
	Left	Right	Total	Middle Frontal	52	58	55
Cerebral White Matter	91	89	90	Inferior Frontal	2	12	4
Cortical Gray Matter	1	1	1	Lateral Orbitofrontal	6	1	2
Ventricles	96	95	95	Medial Orbitofrontal	23	16	17
Subcortical Structures	la man di		and the second	Paracentral	72	74	75
Cerebellar White Matter	98	97	98	Primary Motor	24	15	17
Cerebellar Gray Matter	63	85	75	Parietal Lobes	1	3	2
Brainstem	-	-	19	Primary Sensory	1	1	1
Thalamus	99	99	99	Medial Parietal	8	40	18
Ventral Diencephalon	36	53	44	Superior Parietal	1	5	2

68 yo male, DM2, CD. MRI 1

Intracranial Volume (ICV)	I	CV Percentil	e	Cortical Brain Regions	Percentiles			
(cm ³)			- Contical Brain Regions	Left	Right	Total		
1664.83			Frontal Lobes	19	11	14		
Total Volumes	1	Percentiles		Superior Frontal	60	24	39	
	Left	Right	Total	Middle Frontal	52	58	55	
Cerebral White Matter	91	89	90	Inferior Frontal	2	12	4	
Cortical Gray Matter	1	1	1	Lateral Orbitofrontal	6	1	2	
Ventricles	96	95	95	Medial Orbitofrontal	23	16	17	
Subcortical Structures			1. 200	Paracentral	72	74	75	
Cerebellar White Matter	98	97	98	Primary Motor	24	15	17	
Cerebellar Gray Matter	63	85	75	Parietal Lobes	1	3	2	
Brainstem	-	-	19	Primary Sensory	1	1	1	
Thalamus	99	99	99	Medial Parietal	8	40	18	
Ventral Diencephalon	36	53	44	Superior Parietal	1	5	2	
Basal Ganglia				Inferior Parietal	44	53	49	
Putamen	67	82	75	Supramarginal	5	2	2	
Caudate	91	96	95	Occipital Lobes	1	1	1	
Nucleus Accumbens	98	95	98	Medial Occipital	1	2	1	
Pallidum	7	6	6	Lateral Occipital	1	1	1	
Cingulate	50	55	53	Temporal Lobes	1	1	1	
Anterior Cingulate	91	70	83	Transverse Temporal +			4	
Posterior Cingulate	73	81	79	Transverse Temporal + Superior Temporal			-	
Isthmus Cingulate	2	9	3	Posterior Superior Temporal Sulcus	69	33	49	
				Middle Temporal	1	1	1	
				Inferior Temporal	1	11	3	
				Fusiform	8	17	10	
				Parahippocampal	98	48	87	
				Entorhinal Cortex	1	8	2	

Temporal Pole


Hippocampus

Amygdala




69 yo male, DM2, CD. MRI 2

Structure	e Total Volume (cm ³)		Percentile Cortical Brain Regions		Percentiles Left Right Total				
						Right	Total		
Intracranial Volume			-	Frontal Lobes	84	73	79		
Whole Brain	1049		1	Superior Frontal	92	71	86		
Forebrain Parenchyma	900		1	Middle Frontal	42	47	43		
Total Volumes		Percent	iles	Inferior Frontal	39	89	71		
Total Volumes	Left	Right	t Total	Lateral Orbitofrontal	59	18	37		
Cerebral White Matter	1	1	1	Medial Orbitofrontal	50	26	33		
Cortical Gray Matter	42	36	39	Paracentral	71	75	75		
Ventricles	98	96	97	Primary Motor	96	87	94		
Cerebral WM	70	75	77	Parietal Lobes	43	53	48		
Hypointensities*				Primary Sensory	39	28	31		
Subcortical Structures	40	20	20	Medial Parietal	36	42	38		
Cerebellar White Matter	40	39	39	Superior Parietal	76	90	87		
Cerebellar Gray Matter	50	42	46	Inferior Parietal	75	80	81		
Brainstem		-	46	Supramarginal	7	1	1		
Thalamus	72	57	64	Occipital Lobes	1	1	1		
Ventral Diencephalon	77	84	82	Medial Occipital	2	4	2		
Basal Ganglia				Lateral Occipital	6	4	3		
Putamen	23	29	25	Temporal Lobes	47	23	34		
Caudate	72	74	74	Transverse Temporal +		15	10		
Nucleus Accumbens	63	88	79	Superior Temporal	27	15	18		
Pallidum	16	12	12	Posterior Superior	40	16	21		
Cingulate	18	63	41	Temporal Sulcus					
Anterior Cingulate	75	86	85	Middle Temporal	42	13	22		
Posterior Cingulate	10	16	11	Inferior Temporal	85	76	84		
Isthmus Cingulate	10	33	16	Fusiform	42	18	27		
				Parahippocampal	99	97	99		
				Entorhinal Cortex	23	64	40		
				Temporal Pole	52	25	36		
				Amygdala	74	80	78		
				Hippocampus	27	53	40		



46 YO male, DM2



Comp. Metabolic Panel (14)

	Test	Current Resu	lt and Flag	Previous Result and Date	Units	Reference Interval
	Glucose 01	282	High		mg/dL	65-99
	BUN ⁰¹	16			mg/dL	6-24
	Creatinine ⁰¹	0.94			mg/dL	0.76-1.27
	eGFR If NonAfricn Am	97			mL/min/1.73	>59
T	Carbon Dioxide, Total ⁰¹	19	Low		mmol/L	20-29
	Calcium ⁰¹	9.1			mg/dL	8.7-10.2
	Protein, Total ⁰¹	6.3			g/dL	6.0-8.5
	Test	Current Resu	ult and Flag	Previous Result and Date	Units	Reference Interval
	Lipids ⁰¹					
	Cholesterol, Total ⁰¹	222	High		mg/dL	100-199
	Triglycerides ⁰¹	120			mg/dL	0-149
V	HDL Cholesterol ⁰¹	38	Low		mg/dL	>39
	VLDL Cholesterol Cal	22			mg/dL	5-40
	LDL Chol Calc (NIH)	162	High		mg/dL	0-99
	T. Chol/HDL Ratio	5.8	High		ratio	0.0-5.0
	Test	Current Res	ult and Flag	Previous Result and Date	Units	Reference Interval
•	C-Peptide, Serum ⁰¹	1.0 C-Peptide refe	Low rence interval	is for fasting patients.	ng/mL	1.1-4.4
	Test	Current Res	ult and Flag	Previous Result and Date	Units	Reference Interval
•	Hemoglobin A1c ⁰¹	14.6 **Verified by	High repeat analysi	s**	%	4.8-5.6
	Please Note: 01					
		Diabe	abetes: 5.7 - tes: >6.4			
		Glyce	mic control fo	r adults with diabetes: <7.0	9	
	Estim. Avg Glu (eAG)	372			mg/dL	
		C	ult and Flag	Previous Result and Date	Units	Reference Interval
	Test					




7/5 update

LP+Chol/HDL+LDL/HDL+CHD Risk

Test	Current Result and Flag		Previous Result and Date		Units	Reference Inter	
Lipids ⁰¹							
Cholesterol, Total ⁰¹	170		222	02/11/2022	mg/dL	100-199	
Triglycerides ⁰¹	82		120	02/11/2022	mg/dL	0-149	
HDL Cholesterol ⁰¹	55		38	02/11/2022	mg/dL	>39	
VLDL Cholesterol Cal	15		22	02/11/2022	mg/dL	5-40	
LDL Chol Calc (NIH)	100	High	162	02/11/2022	mg/dL	0-99	
T. Chol/HDL Ratio	3.1		5.8	02/11/2022	ratio	0.0-5.0	
Please Note: 01							
				T. Chol/H			
					Men Women		
				1/2 Avg.Risk			
				Avg.Risk			
				2X Avg.Risk			
				3X Avg.Risk	23.4 11.0		
Estimated CHD Risk	< 0.5		1.2	02/11/2022	times avg.	0.0-1.0	
		The CHD Risk i	s based on th	ne T. Chol/HDL ra	atio. Other		
		factors affect CHD Risk such as hypertension, smoking,					
		factors affect	CHD RISK SUC	ch as hypertensio	on, smoking,		
				and family histor			
LDL/HDL Ratio	1.8	diabetes, seve				0.0-3.6	
LDL/HDL Ratio Please Note: 01	1.8	diabetes, seve	re obesity, a	and family histor	ry of	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	and family histor	ry of ratio	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	and family histor 02/11/2022	ry of ratio	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	and family histor 02/11/2022	ry of ratio Ratio Men Women	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	02/11/2022 LDL/HDL	ry of ratio Ratio Men Women 1.0 1.5	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	02/11/2022 LDL/HDL 1/2 Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2	0.0-3.6	
	1.8	diabetes, seve	re obesity, a	02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0	0.0-3.6	
Please Note: 01	1.8	diabetes, seve	re obesity, a	02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0	0.0-3.6	
	1.8 Current Res	diabetes, seve premature CHD.	re obesity, a	02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0	0.0-3.6 Reference Interva	
Please Note: 01		diabetes, seve premature CHD.	re obesity, a	and family histor 02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk 3X Avg.Risk	ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0 8.0 6.1		
Please Note: 01 Iemoglobin A1c Test	Current Res	diabetes, seve premature CHD.	re obesity, a	and family histor 02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk 3X Avg.Risk 3X Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0 8.0 6.1 Units	Reference Interva	
Please Note: 01 emoglobin A1c Test Hemoglobin A1c ⁰¹	Current Rest	diabetes, seve premature CHD.	re obesity, a	and family histor 02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk 3X Avg.Risk 3X Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0 8.0 6.1 Units	Reference Interva	
Please Note: 01 emoglobin A1c Test Hemoglobin A1c 01	Current Res 7.2 Predia	diabetes, seve premature CHD. ult and Flag High	re obesity, a	and family histor 02/11/2022 LDL/HDL 1/2 Avg.Risk Avg.Risk 2X Avg.Risk 3X Avg.Risk 3X Avg.Risk	ry of ratio Ratio Men Women 1.0 1.5 3.6 3.2 6.2 5.0 8.0 6.1 Units	Reference Interva	





75 yo female. Hypothyroidism.

LP+Chol/HDL+LDL/HDL+CHD Risk

Test	Current Result and Flag		Previous Result and Date		Units	Reference Interval	
Lipids ⁰¹							
Cholesterol, Total ⁰¹	173		181	09/02/2021	mg/dL	100-199	
Triglycerides ⁰¹	186	High	319	09/02/2021	mg/dL	0-149	
HDL Cholesterol ⁰¹	68		43	09/02/2021	mg/dL	>39	
VLDL Cholesterol Cal	31		52	09/02/2021	mg/dL	5-40	
LDL Chol Calc (NIH)	74		86	09/02/2021	mg/dL	0-99	
T. Chol/HDL Ratio	2.5		4.2*	09/02/2021	ratio	0.0-5.0	


Thyroid Panel With TSH


Test	Current Resu	lt and Flag	Previous Result and Date		Units	Reference Interval	
TSH ⁰¹	7.440	High	4.22	09/02/2021	ulU/mL	0.450-4.500	
 Thyroxine (T4) ⁰¹	6.5		6.5	09/02/2021	ug/dL	4.5-12.0	
T3 Uptake ⁰¹	24		26	09/02/2021	%	24-39	
Free Thyroxine Index	1.6		1.7	09/02/2021		1.2-4.9	

Thyroid Antibodies

 Test	Current Resul	t and Flag	Previous Result and Date		Units	Reference Interval
Thyroid Peroxidase (TPO) Ab ⁰¹	9		10	09/02/2021	IU/mL	0-34
Thyroglobulin Antibody ⁰¹	58.8	High	180.3	09/02/2021	IU/mL	0.0-0.9
	Thyroglobulin A	ntibody measu	red by Beckman	Coulter Methodo	logy	

ંક્ર ર







Epigenetics:

Study of changes in the DNA that do not involve changes in the DNA sequence.







Customizable Treatment Protocols





The Blood Test Results Comparative Report lists the results of your patient's latest and previous Chemistry Screet and CBC and shows you whether or not an individual biomarker is outside of the optimal range and/or outside of the clinical lab range.

TOTAL NUMBER OF BIOMARKERS BY OPTIMAL RANGE

Current 0	•	•	46 15	4	•
Trevious	•	•	46 0		
Alarm Low	Below Standard	Below Optimal	Optimal Optimal	Above Standard	Alarm High
Biomarker	Previous Jan 27, 2021	Current Jun 14, 2021	Optimal Range	Standard Range	Units
Glucose	4 91.00	89.00	75.00 - 86.00	65.00 - 99.00	mg/dL
Hemoglobin A1C	5.50		4.50 - 5.50	0.00 - 5.70	%
Insulin - Fasting	2.00	6.80	2.00 - 5.00	2.00 - 19.00	µIU/ml
BUN	11.00		10.00 - 16.00	7.00 - 25.00	mg/dL
Creatinine	0.83		0.80 - 1.10	0.40 - 1.50	mg/dL
BUN/Creatinine Ratio	13.25		10.00 - 16.00	6.00 - 22.00	Ratio
PSA - Total	0.60		0.00 - 2.60	0.00 - 4.00	ng/ml
eGFR Non-Afr. American	95.20		90.00 - 120.00	60.00 - 120.00	mL/min/1.73m
Sodium	140.00		135.00 - 142.00	135.00 - 146.00	mEq/L
Potassium	4.10		4.00 - 4.50	3.50 - 5.30	mEq/L
Sodium/Potassium Ratio	34.15		30.00 - 35.00	30.00 - 35.00	Ratio
Chloride	100.00		100.00 - 106.00	98.00 - 110.00	mEq/L
CO2	26.00		25.00 - 30.00	19.00 - 30.00	mEq/L

Your Workup



Our Know-How

Outcomes





zeb@biogenetix.com p: 833-525-0001

